Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepatitis C Viral Kinetics in HIV/HCV Coinfection
NCT00018031Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2001
- Primary completion
- Apr 2009
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2b in hepatitis C (HCV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response. Started Jun 2001; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00018031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00018031.